Objective A number of vasculo-protective roles have been reported for adiponectin. In contrast, higher, rather than lower, plasma adiponectin levels are associated with an increased risk of cardiovascular disease and mortality in patients undergoing hemodialysis (HD). The mechanisms by which high adiponectin levels are associated with adverse outcome are unclear. Methods This study measured the level of total and high molecular weight (HMW) adiponectins in 70 patients with HD patients (age: 65.2±8.6 years, man/woman: 30/40), and examined the association between adiponectins, metabolic and echocardiographic parameters. Results Women had a significantly higher total, HMW levels and HMW to total ratio than men. The levels of total and HMW adiponectin were positively correlated with those of HDL-cholesterol and B-type natriuretic peptide (BNP) levels, and negatively associated with body mass index (BMI), triglyceride, high sensitive-C reactive protein (CRP) and hemoglobin levels. A multiple linear regression analysis showed that HMW adiponectin had an independent association with BMI (β=-0.270, p=0.003), HDL-cholesterol (β= 0.356, p<0.001), hemoglobin (β=-0.180, p=0.034) and BNP (β=0.200, p=0.014) as total did adiponectin. Conclusion Anemia and BNP levels had independent influence on the total and HMW adiponectin levels in chronic HD patients.
Introduction
Adiponectin is an adipose tissue-specific protein, and plays multiple protective roles associated with insulinsensitivity, inflammation and atherosclerosis (1) . The plasma adiponectin level is inversely correlated with body mass index (BMI) (2, 3) , and has also been suggested to play a protective role in the development of cardiovascular comorbidities. The plasma adiponectin level is reduced in various nonuremic high-risk subjects, such as patients with obesity, dyslipidemia, hypertension, type 2 diabetes mellitus and cardiovascular disease (CVD) (2) (3) (4) (5) . High levels of adiponectin in the general population are associated with fewer CV complications, such as coronary artery disease (3) and myocardial infarction (5) . However, a high adiponectin level in patients undergoing hemodialysis (HD) is thought to be associated with a high CV mortality and/or all cause mortality (6, 7) . A recent cohort study showed that the level of adiponectin is associated with increased mortality in patients with chronic kidney disease (CKD) (8) and progressive decline of renal function (9) . On the other hand a decrease in the total adiponectin level is an independent predictor for CVD events (10) and associated with insulin resistance and prevalent CVD among patients with CKD and/or HD patients (11, 12) . In spite of experimental evidence, clinical studies have demonstrated inconsistent results concerning the association between adiponectin and the risk of CVD and mortality, and the precise mechanisms of these phenomena are not fully understood.
Three major adiponectin isoforms are present in plasma; low molecular weight (LMW) trimers, middle molecular weight (MMW) hexamers, and high molecular weight (HMW) multimers. Clinical and basic studies suggest that HMW adiponectin has the greatest cardiovascular protective effect (13, 14) . The level of total and HMW adiponectin has a positive association with the B-type natriuretic peptide (BNP) level (15, 16) and BNP increases adiponectin synthesis in cultured human adipocytes (17) . BNP is synthesized in the ventricular myocardium in response to ventricular stretching and wall stress (18) , and plasma BNP levels have prognostic potential for patients with end-stage renal disease (ESRD) (19) . The elevation of HMW adiponectin is also associated with anemia in CKD patients with diabetes (20) . Anemia is common in patients with ESRD and is a risk factor for adverse outcome (21) .
This study tested the hypothesis that plasma BNP levels and anemia might reflect the adiponectin level in chronic HD patients. The study also evaluated left ventricular mass index (LVMI) and ejection fraction (EF) at the same time, since BNP levels are strongly associated with LV hypertrophy and systolic dysfunction in patients with ESRD (19) .
Material and Methods

Study population
This study included 70 patients with ESRD (30 men and 40 women) on maintenance HD for more than 6 months. The patients were treated 12 to 15 hours per week with standard bicarbonate dialysis. The average urea Kt/V in these patients was 1.2±0.2. The underlying kidney diseases were chronic glomerulonephritis (n=37), diabetes (n=16), hypertensive nephrosclerosis (n=9), polycystic kidneys (n=4) and others (n=4). The diabetic patients on HD were defined by persistent albuminuria, diabetic retinopathy, but no clinical or laboratory evidence of other kidney diseases. The subjects had no clinical evidence of heart failure defined as dyspnea [New York Heart Association (NYHA) classes I to II] in addition to jugular vein dilatation, moist rales, interstitial edema on chest X-ray. Patients that had received one or more lipid-lowering agents or had acute infectious diseases were excluded from this study. Written informed consent was obtained from each patient. This study was approved by the institutional review board (the Ethics Committee of Fukuoka University Hospital).
Blood sampling and laboratory measurement
Blood samples were obtained at the start of the dialysis session 2 days after the previous hemodialysis, in the morning after an overnight fasting. Routine analysis including total cholesterol (TC), high density lipoprotein cholesterol (HDL-C), and triglyceride (TG) were measured by routine laboratory methods. low density lipoprotein (LDL) cholesterol concentrations were calculated using the Friedewald formula. Insulin resistance as assessed by homeostasis model assessment (HOMA-IR) was calculated using the formula: HOMA-IR = fasting glucose (mg/dl) × fasting insulin (μU/ml)/405. Plasma was separated by centrifugation at 2,500 g for 15 min at 4 , and kept frozen at -80 until analysis. High sensitive c-reactive protein (hs-CRP) levels were measured by the latex-enhanced immunonephelometric assay (N Latex CRP, Dade Behring, Liederbach, Germany). Plasma total adiponectin and HMW adiponectin were measured by the originally described by Ebinuma et al. (Human Adiponectin ELASA kit for Total and Multimer, Daiichi Pure Chemicals, Tokyo, Japan) (22) . Plasma BNP was determined with an EIA kit (Tosho Corporation, Tokyo, Japan).
Transthoracic ultrasound echocardiography
Echocardiographic examinations were performed the day before hemodialysis including M-mode, two-dimensional, conventional Doppler, and color Doppler echocardiography. Left ventricular mass (LVM) was calculated as 1.04 × {[LV internal dimension at end-diastole (LVDd) + intraventricular septal thickness (IVST) + LV posterior wall thickness (LVPWT)] 3 -(LVDd) 3 } -13.6 according to Devereux et al. (23) , and LVMI was calculated by dividing the cardiac mass by the body surface area.
Statistical analysis
All data analyses were performed using SPSS software package (Version 11.0 for windows, Chicago, IL). Data are expressed as the mean ± standard deviation (SD), or the median and interquartile range. Comparisons between two groups were compared by Student's t-test or the MannWhitney U-test. Differences in the prevalence between groups were assessed by the chi-squared test. Correlations between variables were examined by a linear regression analysis. A forward stepwise multiple linear regression analysis was used to determine the factors independently associated with total and HMW adiponectin. Distribution was tested for normality using the Shapiro-Wilk W test; and nonnormally distributed parameters were log-transformed before the analysis. A p value less than 0.05 was considered to be significant.
Results
Effects of sex and diabetes on total and HMW adiponectin Table 1 summarizes the clinical and biochemical characteristics of the study population. Women had significantly higher serum levels of TC, HDL-C, and LDL-C levels than did men. Women had higher plasma levels of total, HMW adiponectin and the ratio of HMW to total adiponectin than men. However, there were no significant differences in the Table 2 shows the univariate correlations between the total, HMW adiponectin and the characteristics of the study population. A simple regression analysis showed that the total adiponectin levels were positively correlated with age, HDL cholesterol and BNP. In addition, total adiponectin showed a inverse correlation with BMI, TG, HOMA-IR, hs-CRP. Similarly, HMW adiponectin levels were positively related with HDL-C, and negatively with BMI, TG, HOMA-IR, hs-CRP. Total and HMW adiponectin showed a positive correlation with BNP and negative with Hb ( Figure A-D) . These correlations were similar when the data were stratified by sex (data not shown). A multiple linear regression analysis showed that HMW adiponectin had an independent association with BMI (β=-0.270, p=0.003), HDL-C (β=0.356, p< 0.001), Hb (β=-0.180, p=0.034), BNP (β=0.200, p=0.014) and female gender (β=0.289, p=0.001) as did total adiponectin (Table 3) .
Correlations between total, HMW adiponectin and metabolic parameters
Discussion
Adiponectin has been shown to have favorable effects associated with insulin-sensitivity, inflammation and lipid metabolism (1). Although healthy subjects were not assayed in the present study, some investigators report that dialysis patients have two-to threefold increased total adiponectin levels in comparison to healthy subjects. However, alterations in synthesis, secretion, or clearance of adiponectin oligomeric forms in a uremic state are poorly identified. On the other hand, the elevated adiponectin levels are a risk factor for CVD events and all cause mortality not only in patients on hemodialysis (6, 7) but also in patients with coronary artery disease (24) and congestive heart failure (CHF) (15) . The reason why high adiponectin levels are associated with adverse outcomes in ESRD is unclear.
One possibility is the increased energy expenditure in hemodialysis (25) and CHF (26) . Adiponectin is suggested to increase energy expenditure and induce weight loss through a direct effect on the brain (27) . Actually the association between adiponectin level and BMI was confirmed by a multiple linear regression analysis in the present study, and elevation of plasma adiponectin levels in association with increased energy expenditure might have negative effect on patients receiving HD.
Interestingly, there was a positive association of total and HMW adiponectin with the BNP level. This finding is consistent with several studies in healthy populations (16) , HF (15) and HD patients (28) . Furthermore, increasing adiponectin is associated with higher risks of CV outcomes and death in diabetic HD patients, and this association is mainly explained by a confounding effect of N-terminal pro-B-type natriuretic peptide (NT-pro-BNP) (6). NT-proBNP has a longer half-life and larger size, and is more dependent on renal clearance than BNP (29) . Cardiac natriuretic peptides, AMP and BNP, have a novel lipolytic and potential lipidmobilization effect that is mediated by specific adipocyte membrane receptors (30) . They increase adiponectin mRNA expression and adiponectin synthesis from cultured human adipocytes via a cGMP-dependent pathway (17) . Although a positive relationship has been observed between plasma adiponectin and LVMI in diabetic HD patients (28), the current The current study also found that Hb was an independent determinant of the total and HMW adiponectin level in patients with HD. Anemia was associated with marked elevation of serum total and HMW adiponectin level, and this elevation was independent of renal function. The level of plasma total adiponectin negatively correlates with Hb in CKD with and without diabetes (20) . Furthermore, a significant positive correlation between serum HMW adiponectin and erythropoietin level was clearly demonstrated in the current series. In fact anemia induces the expression of hypoxia inducible factor (HIF) by affected tissue cells, and HIF-1 up-regulates the expression of adiponectin in white adipose tissue, microvascular endothelial cells, or diabetic hearts in mice (31) . In addition, the adiponectin gene has the putative HIF-1 response elements in the promoter region in mice (32) . These mechanisms may underlie the finding that Hb was one of independent determinants of the adiponectin level.
The present study showed the total and HMW adiponectin levels to be positively associated with BNP, and negatively with hemoglobin in chronic hemodialysis patients. The conditions of renal failure, heart failure, and anemia affect each other in patients with CKD complicated with cardio-vascular disease, creating what is called Cardio-Renal-Anemia syndrome (33) . Such renal insufficiency may cause anemia through reduced erythropoietin production and bone marrow activity. The fluid retention causes plasma volume expansion, which leads to LV dilatation and stress on an already stressed myocardium. The consequent LV hypertrophy leads to necrosis and apoptosis of myocardial cells, myocardial fibrosis and cardiomyopathy resulting in CHF. In addition, elevated levels of renin, angiotensin and aldosterone cause damage to cardiac cells directly, exacerbating the damage already done. The level of plasma adiponectin in a patient with this syndrome should be apparently high consistent with the current findings, but it is not yet precisely known. Further studies are thus required.
Some limitations associated with this study should be considered. First, the study did not provide any information regarding body composition, which might give a more precise indication of the nutrition and volume status. Second, this study was a cross-sectional study of a small number of subjects, and the results should be confirmed in a larger study.
In conclusion, total and HMW adiponectin were independently associated with anemia and BNP in chronic hemodialysis patients. These findings may partly be explained by the fact that HD patients with a high adiponectin level had poor prognosis due to the 'adiponectin paradox'. Total adiponectin is more useful to assess the risk of mortality than HMW adiponectin in CHF patients, and a high plasma total adiponectin is an independent prognostic predictor (34) . Moreover, LMW adiponectin is independently associated with hs-CRP and TG in non-diabetic HD patients (35) . Further studies are needed to determine the role of adiponectin and its multimers in hemodialysis patients.
